Cystic Fibrosis Weekly Update
Contents:- #ECFS2018 – Orkambi Taken for 1 Year Returned Glucose Levels to Normal in Group of CF Patients in Study
- #ECFS2018 – Potential CFTR Corrector PTI-801, Plus Orkambi, Seen to Treat CF Patients in Phase 1 Trial
- #ECFS2018 – Kalydeco’s Benefits Include Lower Risk of Death and Pulmonary Flares, Real-world Data Shows
- #ECFS2018 – ARRIVAL Trial Shows Kalydeco to Improve Outcomes in Toddlers, Other Studies Support Real-life Benefits
- #ECFS2018 – Tobacco Smoke Exposure Greatly Speeds Loss of Lung Function in Children with CF, Study Reports
- #ECFS2018 — Next-Generation CFTR Correctors for Cystic Fibrosis Show Promise in Early Trial Data
- #ECFS2018 — Hard-to-Treat Infections May Not Impact Survival of CF Patients After Lung Transplant, Study Shows
- #ECFS2018 – HOPE-1 Trial Shows Potential of SPX-101 to Improve Lung Function in CF Patients
- Guidelines Needed for Listing CF Patients with Nontuberculous Mycobacteria Infections for Lung Transplants, Survey Finds
- #ECFS2018 – Proteostasis Therapeutics Provides Update on CF Clinical Development Program
.png)
No hay comentarios:
Publicar un comentario